The French company will supply masitinib and more than 130 of its proprietary drugs that have demonstrated activity against 3CL-Pro -- the main protease necessary for the SARS-CoV-2 viral replication cycle. Using its proprietary research platform, the university will enhance the preclinical program of masitinib against SARS-CoV-2, as well as investigate the use of masitinib against other viruses that are dependent on the 3CL-Pro protease for replication, AB Science said. In addition, the institution will test and identify analogs of masitinib that are active against 3CL-Pro.

AB Science and the University of Chicago will also merge their patent rights related to masitinib or masitinib analogs related to virology applications. If any products are discovered using AB Science products and then commercialized, AB Science will pay the university 1% of net sales for the first registered product and 0.3% of net sales for other registered products.

AB Science gets loan for COVID-19 treatment development
The European Investment Bank has signed a loan agreement with AB Science totaling 15 million euros ($17.9 million U.S.) that will enable AB...

New model could improve vaccine, immunotherapy design
A new model used to predict the outcomes of pathogen detection systems as a function of innate immunity may lead to more effective cancer immunotherapies...

New technique reins in inflammatory response of adjuvants
Adjuvants are often added to vaccines as a method for promoting an immune response in recipients. But what happens when that immune response goes haywire,...

COVID-19 vaccine based on peptide nanofibers shows promise
A new technology platform using self-assembling peptide nanofibers tagged with antibodies can be an effective SARS-CoV-2 vaccine, according to a proof-of-concept...

Bio-Rad wins appeal in 10x Genomics patent infringement ruling
Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed...